|Nombre||Título||Pagar||Ejecutado||Año de nacimiento|
|Mr. Michael Sen||CEO, Pres & Chairman of Management Board - Fresenius Management SE||2.91M||N/D||1968|
|Ms. Sara Lisa Hennicken||CFO & Member of the Management Board - Fresenius Management SE||919k||N/D||1980|
|Dr. Sebastian Biedenkopf||Chief Legal Officer, HR, Labor Relations Director, Risk Mgmt & Member of Mgmt. Board||1.51M||N/D||1964|
|Ms. Helen Giza||Member of the Management Board - Fresenius Management SE||1.98M||N/D||1968|
|Mr. Pierluigi Antonelli||Member of Management Board of Fresenius Management SE & CEO of Fresenius Kabi||N/D||N/D||N/D|
|Dr. Michael Sven Moser Ph.D.||Member of Management Board of Fresenius Management SE||N/D||N/D||1977|
|Mr. Robert Moller||Member of the Management Board of Fresenius Management SE||N/D||N/D||1970|
|Mr. Markus Georgi||Sr. VP of Investor Relations||N/D||N/D||N/D|
|Matthias Link||Sr. VP Corp. Communications||N/D||N/D||N/D|
Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
La calificación ISS Governance QuickScore de Fresenius SE & Co. KGaA a partir del 1 de septiembre de 2023 es 2. Las puntuaciones principales son Auditoría: 1; Junta: 3; Derechos del accionista: 1; Compensación: 2.